AI MARKET SCANNING

Arrowhead Pharmaceuticals, Inc.

📅 Next Catalyst: Nov 23, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP -0.10%
MAX GAP RECORD +12.74%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $ARWR
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 23, 2026 Earnings Release 2026-11-23 (AFTER CLOSE) 🔮 UPCOMING 🔒
Aug 04, 2026 Earnings Release 2026-08-04 (AFTER CLOSE)
-2.34%
May 07, 2026 Earnings Release 2026-05-07 (AFTER CLOSE)
-1.86%
Feb 05, 2026 Earnings Release 2026-02-05 (AFTER CLOSE)
+1.33%
Nov 25, 2025 Earnings Release 2025-11-25 (AFTER CLOSE)
+1.28%
Aug 07, 2025 Earnings Release 2025-08-07 (AFTER CLOSE)
-3.18%
May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE)
+12.74%
Feb 10, 2025 Earnings Release 2025-02-10 (AFTER CLOSE)
-8.48%

VOLATILITY & GAP BIAS

AVG GAP MOVE 3.9%
Bullish Gaps (6)
Bearish Gaps (8)
Neutral / Flat (1)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $ARWR

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗